Abstract 4361629: Preservation of Acetyl-Coenzyme A Synthetase 2 Sustains Cytosolic Acetyl-CoA and Protects Against Heart Failure

T Toranosuke Sekine (Fukushima Medical University, Fukushima, Japan) S Shunsuke Miura (Fukushima Medical University, Fukushima, Japan) S Satoshi Okochi (Fukushima Medical University, Fukushima, Japan) R Ryo Ogawara (Fukushima Medical University, Fukushima, Japan) T Tetsuro Yokokawa (Fukushima Medical University, Fukushima, Japan) T Tomofumi Misaka (Fukushima Medical University, Fukushima, Japan) M Masayoshi Oikawa (Fukushima Medical University, Fukushima, Japan) K Kazuhiko Nakazato (Fukushima Medical University, Fukushima, Japan) T Takafumi Ishida Y Yasuchika Takeishi (Fukushima Medical University, Fukushima, Japan)

Abstract

Background: Emerging evidence suggests that the homeostasis of cytosolic acetyl-coenzyme A (acetyl-CoA) is critical for maintaining cardiac function, especially under pathological stress. Acetyl-CoA serves as a central metabolic intermediate, linking nutrient catabolism to mitochondrial energy production and epigenetic regulation through protein acetylation. However, the enzymatic pathways that control cytosolic acetyl-CoA levels in the heart remain poorly defined. Acetyl-CoA synthetase 2 (ACSS2), which converts acetate into acetyl-CoA in the cytosol, may play a key role in regulating this metabolic pool. This study aimed to investigate the role of ACSS2 in cardiomyocyte metabolism and adaptation in response to isoproterenol. Methods: In vivo, mice were infused with isoproterenol via osmotic pump to induce heart failure, and cardiac function was assessed using echocardiography. In vitro, H9c2 cardiomyoblasts were treated with isoproterenol and subjected to either pharmacological inhibition or CRISPR/Cas9-mediated knockout of ACSS2. Cytosolic acetyl-CoA and mitochondrial respiration were measured using targeted metabolite assays and seahorse XF analysis. ACSS2 was overexpressed using lentiviral vectors. Short- and medium-chain fatty acids, specifically butyrate and octanoate, were supplemented to bypass mitochondrial transport steps and assess mitochondrial function. Results: Western blot analysis showed that ACSS2 expression was significantly reduced in the myocardium of isoproterenol-treated mice (Fig. 1A), with a corresponding decrease in cytosolic acetyl-CoA levels (Fig. 1B). In H9c2 cells, isoproterenol similarly reduced ACSS2 expression (Fig. 2A) and cytosolic acetyl-CoA (Fig. 2B). Isoproterenol impaired mitochondrial respiration, with reductions in basal, maximal, and ATP-linked respiration (Fig. 2C). Both pharmacological inhibition and genetic deletion of ACSS2 impaired mitochondrial respiration. In contrast, ACSS2 overexpression preserved mitochondrial function under isoproterenol stress (Fig. 3). Supplementation with butyrate or octanoate partially improved mitochondrial respiration, but did not fully rescue mitochondrial function, suggesting that cytosolic acetyl-CoA depletion causes mitochondrial dysfunction beyond substrate limitation. Conclusions: ACSS2 is essential for maintaining cytosolic acetyl-CoA levels and mitochondrial function during cardiac stress. These findings support acetate metabolism as a therapeutic target for heart failure.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (10)

T

Toranosuke Sekine

Fukushima Medical University, Fukushima, Japan

S

Shunsuke Miura

Fukushima Medical University, Fukushima, Japan

S

Satoshi Okochi

Fukushima Medical University, Fukushima, Japan

R

Ryo Ogawara

Fukushima Medical University, Fukushima, Japan

T

Tetsuro Yokokawa

Fukushima Medical University, Fukushima, Japan

T

Tomofumi Misaka

Fukushima Medical University, Fukushima, Japan

M

Masayoshi Oikawa

Fukushima Medical University, Fukushima, Japan

K

Kazuhiko Nakazato

Fukushima Medical University, Fukushima, Japan

T

Takafumi Ishida

Y

Yasuchika Takeishi

Fukushima Medical University, Fukushima, Japan